Alimera Sciences

$7.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.51 (-6.22%) As of 6:49 PM UTC today

Why Robinhood?

You can buy or sell ALIM and other stocks, options, and ETFs commission-free!

About ALIM

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. The listed name for ALIM is Alimera Sciences, Inc. Common Stock.

CEO
Richard S. Eiswirth
Employees
127
Headquarters
Alpharetta, Georgia
Founded
2003
Market Cap
38.98M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
76.46K
High Today
$8.13
Low Today
$7.45
Open Price
$8.10
Volume
38.86K
52 Week High
$10.79
52 Week Low
$2.86

ALIM Earnings

-$1.44
-$0.93
-$0.43
$0.08
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.04 per share
Actual
-$0.18 per share
Replay Earnings Call

You May Also Like

PGF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure